Skip to main content
Fig. 1 | Lipids in Health and Disease

Fig. 1

From: Changes in lipoprotein lipase and endothelial lipase mass in familial hypercholesterolemia during three-drug lipid-lowering combination therapy

Fig. 1

Study design. The present study was conducted as a prospective open randomized study to investigate the efficacy and safety of coadministration of rosuvastatin at 20 mg/day, ezetimibe at 10 mg/day, and granulated colestimide at 3.62 g/day. Any lipid-lowering agents had been washed out ≥ 4 weeks before entry into the study. Study subjects were divided into two groups by an envelope-based method to elucidate the secondary end point of the present study: rosuvastatin at 20 mg/day (group 1) versus rosuvastatin at 10 mg/day coadministered with ezetimibe at 10 mg/day (group 2). The white, blue, pink, and purple arrows indicate baseline, second, third, and last blood sampling, respectively

Back to article page